|1.||Brophy, Colleen M: 3 articles (07/2010 - 03/2009)|
|2.||Flynn, Charles R: 2 articles (07/2010 - 03/2009)|
|3.||Furnish, Elizabeth J: 2 articles (03/2010 - 03/2009)|
|4.||Arno, Anna I: 1 article (06/2014)|
|5.||Barret, Juan P: 1 article (06/2014)|
|6.||Gauglitz, Gerd G: 1 article (06/2014)|
|7.||Jeschke, Marc G: 1 article (06/2014)|
|8.||Smoke, Christopher C: 1 article (07/2010)|
|9.||Cheung-Flynn, Joyce: 1 article (07/2010)|
|10.||Sheller, Michael R: 1 article (07/2010)|
03/01/2009 - "Taken together, these results suggest the potential use of AZX100 as a strategy to prevent excessive scarring and fibrotic disorders."
03/01/2009 - "We also examined the effect of AZX100 on scar formation in vivo in dermal wounds in a Siberian hamster model. "
03/01/2009 - "In vivo, AZX100 significantly improved collagen organization in a Siberian hamster scarring model. "
07/01/2010 - "Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts."
03/01/2009 - "Treatment with AZX100 decreased stress fiber formation and altered the morphology of human dermal keloid fibroblasts. "
03/01/2009 - "In the present study, we evaluated the effect of AZX100, a phosphopeptide analogue of HSP20, on transforming growth factor-beta-1 (TGF-beta1)-induced CTGF and collagen expression in human keloid fibroblasts. "
06/01/2014 - "Peptides such as the transforming growth factor beta (TGF-β) superfamily, with Smads, Ski, SnoN, Fussels, endoglin, DS-Sily, Cav-1p, AZX100, thymosin-β4 and other related molecules may emerge as targets to prevent and treat keloids and hypertrophic scars. "
|3.||Hypertrophic Cicatrix (Hypertrophic Scar)
|4.||Wounds and Injuries (Trauma)
|5.||Hypotension (Low Blood Pressure)
|2.||Transforming Growth Factor beta (TGF-beta)